Citadel Advisors
STRO icon

Citadel Advisors’s Sutro Biopharma STRO Stock Holding History

Citadel Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Buy
117,537
+85,452
+266% +$1.54M ﹤0.01% 5313
2025
Q4 		$371K Buy
+32,085
New +$304K ﹤0.01% 9694
2025
Q2 		– Sell
-14,123
Closed -$115K – 14983
2025
Q1 		$91.9K Sell
14,123
-231,743
-94% -$3.65M ﹤0.01% 11594
2024
Q4 		$4.52M Buy
245,866
+33,200
+16% +$1.01M ﹤0.01% 4119
2024
Q3 		$7.36M Buy
212,666
+50,675
+31% +$1.99M ﹤0.01% 3360
2024
Q2 		$4.75M Buy
161,991
+127,917
+375% +$5.06M ﹤0.01% 3829
2024
Q1 		$1.93M Buy
34,074
+20,881
+158% +$922K ﹤0.01% 5603
2023
Q4 		$566K Buy
13,193
+8,334
+172% +$264K ﹤0.01% 7823
2023
Q3 		$169K Buy
4,859
+2,026
+72% +$88.3K ﹤0.01% 10175
2023
Q2 		$132K Sell
2,833
-30,084
-91% -$1.5M ﹤0.01% 10521
2023
Q1 		$1.52M Buy
32,917
+20,917
+174% +$1.33M ﹤0.01% 5885
2022
Q4 		$970K Sell
12,000
-18,209
-60% -$1.27M ﹤0.01% 6877
2022
Q3 		$1.68M Sell
30,209
-31,361
-51% -$1.86M ﹤0.01% 5930
2022
Q2 		$3.21M Buy
61,570
+25,785
+72% +$1.44M ﹤0.01% 4637
2022
Q1 		$2.94M Sell
35,785
-23,892
-40% -$2.27M ﹤0.01% 5236
2021
Q4 		$8.88M Sell
59,677
-7,287
-11% -$1.31M ﹤0.01% 3272
2021
Q3 		$12.7M Sell
66,964
-9,035
-12% -$1.72M ﹤0.01% 2669
2021
Q2 		$14.1M Sell
75,999
-21,663
-22% -$4.24M ﹤0.01% 2561
2021
Q1 		$22.2M Sell
97,662
-31,638
-24% -$7.51M 0.01% 1828
2020
Q4 		$28.1M Buy
129,300
+7,287
+6% +$1.21M 0.01% 1451
2020
Q3 		$12.3M Sell
122,013
-5,139
-4% -$486K ﹤0.01% 2051
2020
Q2 		$9.87M Sell
127,152
-27,783
-18% -$2.67M ﹤0.01% 2229
2020
Q1 		$15.8M Sell
154,935
-17,963
-10% -$1.89M 0.01% 1430
2019
Q4 		$19M Sell
172,898
-82
-0% -$8.45K 0.01% 1530
2019
Q3 		$15.7M Buy
172,980
+145
+0.1% +$14.6K 0.01% 1711
2019
Q2 		$19.7M Sell
172,835
-85
-0% -$9.37K 0.01% 1445
2019
Q1 		$19.7M Buy
172,920
+16
+0% +$1.66K 0.01% 1351
2018
Q4 		$15.6M Sell
172,904
-1,938
-1% -$234K 0.01% 1432
2018
Q3 		$26.2M Buy
+174,842
New +$26.4M 0.01% 1180

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's STRO Position: Q1 2026 in Review

Citadel Advisors increased its Sutro Biopharma (STRO) stake by 266% in Q1 2026, buying an estimated $1.54M and bringing the position to 117,537 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #5313.

Citadel Advisors first reported a position in STRO in Q3 2018 and has held it in 29 quarters since. The position peaked at $28.1M in Q4 2020. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Citadel Advisors held 117,537 shares of Sutro Biopharma worth $2.93M as of Q1 2026.
  • Citadel Advisors bought 85,452 Sutro Biopharma shares in Q1 2026, an estimated $1.54M.
  • Sutro Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5313 holding.
  • Citadel Advisors first reported a position in Sutro Biopharma in Q3 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Sutro Biopharma position peaked at $28.1M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.